Agios Pharmaceuticals Inc. (AGIO)’s Financial Results Comparing With Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Both Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agios Pharmaceuticals Inc. 54 24.78 N/A -5.99 0.00
Ligand Pharmaceuticals Incorporated 116 10.61 N/A 35.15 2.60

In table 1 we can see Agios Pharmaceuticals Inc. and Ligand Pharmaceuticals Incorporated’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 has Agios Pharmaceuticals Inc. and Ligand Pharmaceuticals Incorporated’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals Inc. 0.00% -48.2% -38.6%
Ligand Pharmaceuticals Incorporated 0.00% 103.3% 42.8%

Risk & Volatility

Agios Pharmaceuticals Inc. has a beta of 2.17 and its 117.00% more volatile than Standard & Poor’s 500. Ligand Pharmaceuticals Incorporated has a 1.31 beta and it is 31.00% more volatile than Standard & Poor’s 500.

Liquidity

The Current Ratio of Agios Pharmaceuticals Inc. is 6.9 while its Quick Ratio stands at 6.9. The Current Ratio of rival Ligand Pharmaceuticals Incorporated is 8.4 and its Quick Ratio is has 8.3. Ligand Pharmaceuticals Incorporated is better equipped to clear short and long-term obligations than Agios Pharmaceuticals Inc.

Analyst Recommendations

Agios Pharmaceuticals Inc. and Ligand Pharmaceuticals Incorporated Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Agios Pharmaceuticals Inc. 0 0 2 3.00
Ligand Pharmaceuticals Incorporated 0 1 2 2.67

Agios Pharmaceuticals Inc. has an average price target of $75, and a 74.91% upside potential. Ligand Pharmaceuticals Incorporated on the other hand boasts of a $184.67 consensus price target and a 96.35% potential upside. The data from earlier shows that analysts view suggest that Ligand Pharmaceuticals Incorporated seems more appealing than Agios Pharmaceuticals Inc.

Institutional and Insider Ownership

Insiders owned roughly 0.3% of Agios Pharmaceuticals Inc.’s shares. Insiders Competitively, owned 2.9% of Ligand Pharmaceuticals Incorporated shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Agios Pharmaceuticals Inc. 2.49% -2.96% -9.55% -6.82% -43.99% 4.34%
Ligand Pharmaceuticals Incorporated -17.19% -20.32% -27.22% -22.2% -57.51% -32.56%

For the past year Agios Pharmaceuticals Inc. had bullish trend while Ligand Pharmaceuticals Incorporated had bearish trend.

Summary

Ligand Pharmaceuticals Incorporated beats on 7 of the 10 factors Agios Pharmaceuticals Inc.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The companyÂ’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, oncology, allergy, anti-coagulant, depression, sun damage, blood disorders, and diabetes. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis AG; Amgen, Inc.; Merck & Co., Inc.; Pfizer Inc.; Celgene; Gilead Sciences; Janssen Biotech, Inc.; Baxter International, Inc.; and Eli Lilly and Company. The company was founded in 1987 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.